Liver cell therapies using induced pluripotent stem cells (iPSCs) are in development. A recent paper in Nature by Takebe et al. expands the range of liver diseases that could be treated with iPSC-derived hepatocytes by combining them with endothelial and stromal cells to generate organoids that survive and function extrahepatically.